Lineage Cell Therapeutics (LCTX) Non-Current Assets (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Non-Current Assets of $53.4 million for Q1 2026, down 13.6% year-over-year from $61.8 million in Q1 2025, and little changed quarter-over-quarter from $53.4 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Non-Current Assets (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $53.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 13.6% year-over-year to $53.4 million; the TTM figure through Mar 2026 stood at $201.1 million (down 19.09% YoY), while the FY2025 annual figure was $53.4 million, down 14.13% from the prior year.
- Non-Current Assets for Q1 2026 stood at $53.4 million, roughly flat from $53.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $63.7 million in Q4 2022, with the low at $47.0 million in Q2 2025.
- The 5-year median for Non-Current Assets is $62.4 million (2024), against an average of $59.7 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets increased 2.1% in 2023, then fell 24.77% in 2025.
- Lineage Cell Therapeutics' Non-Current Assets stood at $63.7 million in 2022, then fell by 1.71% to $62.6 million in 2023, then fell by 0.57% to $62.2 million in 2024, then slipped by 14.13% to $53.4 million in 2025, then decreased by 0.11% to $53.4 million in 2026.
- Business Quant data shows LCTX's Non-Current Assets at $53.4 million in Q1 2026, $53.4 million in Q4 2025, and $47.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 53.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.25 Mn |
| Mar 31, 2026 | 53.37 Mn |
| Dec 31, 2025 | 53.43 Mn |
| Sep 30, 2025 | 47.38 Mn |
| Jun 30, 2025 | 46.96 Mn |
| Mar 31, 2025 | 61.77 Mn |
| Dec 31, 2024 | 62.22 Mn |
| Sep 30, 2024 | 62.19 Mn |
| Jun 30, 2024 | 62.41 Mn |
| Mar 31, 2024 | 62.77 Mn |
| Dec 31, 2023 | 62.58 Mn |
| Sep 30, 2023 | 62.67 Mn |
| Jun 30, 2023 | 63.20 Mn |
| Mar 31, 2023 | 63.55 Mn |
| Dec 31, 2022 | 63.66 Mn |
| Sep 30, 2022 | 62.64 Mn |
| Jun 30, 2022 | 61.90 Mn |
| Mar 31, 2022 | 62.65 Mn |
| Dec 31, 2021 | 63.00 Mn |
| Sep 30, 2021 | 62.87 Mn |